Background & objectives: Survival of patients with multiple myeloma (MM) has improved in the past two decades following use of novel agents and autologous stem cell transplantation. To determine predictors of long-term outcome, data of MM patients who underwent autologous stem cell transplantation (ASCT) at a tertiary care centre in north India were retrospectively analyzed.
Multiple myeloma (MM), a clonal plasma cell malignancy accounts for approximately 10 per cent of haematologic malignancies. Compared to industrialized nations, myeloma occurs a decade earlier in India, at a median age of 55 yr 1 . Present management of myeloma patients includes novel agents (immunomodulators -thalidomide, lenalidomide, proteasome inhibitors -bortezomib)-based initial (induction) therapy for 4-6 months followed by autologous stem cell transplantation (ASCT) in patients aged ≤65-70 yr without major co-morbidities. This is followed by low-dose maintenance therapy with either lenalidomide or thalidomide or bortezomib for two years. For elderly patients (≥65-70 yr) or those not suitable for ASCT induction, therapy is given for 6-9 months followed by maintenance therapy. The ASCT is an integral component of myeloma management and has contributed to survival improvement in the past two decades 2 . Initial transplant studies have used conventional chemotherapy before ASCT. A number of randomized studies [3] [4] [5] [6] [7] and meta-analyses 8 have confirmed that ASCT is associated with deepening of response rate and improved progression-free survival (PFS) in most and overall survival (OS) in some studies compared to conventional cytotoxic chemotherapy. Subsequently, these results were confirmed in recent randomized studies [9] [10] [11] [12] [13] [14] using novel agents-based induction before ASCT further augmenting responses with improvement in survival. While enough experience with ASCT for long-term outcome has been reported from developed countries [15] [16] [17] [18] [19] [20] , comprehensive information from resource-limited setting like ours, on the long-term outcome following transplant is limited 21 . We have reported our initial experience for MM patients transplanted till the year 2014 22 . Here we report an updated follow up with long-term outcome on patients with MM transplanted between 1995 and 2016 as well as comprehensive analysis of prognostic factors associated with long-term survival.
Material & Methods
The data on 349 consecutive MM patients, who underwent ASCT at Institute Rotary Cancer Hospital, All India Institute of Medical Sciences (AIIMS), New Delhi, India, between 1995 and December 2016 were analysed. The study was approved by the Ethics Committee of AIIMS. The patients' characteristics are shown in Table I . The median age was 52 yr ranging from 29 to 68 yr; 236 (67.6%) were males, 34.7 per cent had international staging system (ISS) Stage III disease and 24.4 per cent had Stage IIIB by Durie-Salmon 24 . Patients were advised maintenance therapy using low-dose thalidomide (50 mg daily) or lenalidomide (5-10 mg/ day) for 21 days every month or injection bortezomib 2 mg subcutaneously twice a month. In addition, patients with adequate estimated glomerular filtration rate (eGFR) (≥60 ml/min) 23,25 also received injection zoledronic acid once in three months for first two years then once in six months indefinitely along with calcium and vitamin D supplement.
Statistical analysis:
An intention-to-treat analysis was done. Descriptive statistics (median and range) were calculated for all variables. Response to transplant was defined as per the EBMT criteria 24 .
The prognostic factors for response to transplant were analyzed by Pearson Chi-square test and binary logistic regression analysis. OS was defined as the time from date of transplant until death or date of censor (December 31, 2017). PFS was calculated from date of transplant to disease progression or death (regardless of the cause of death). Survival curves were plotted according to the method of Kaplan and Meier 26 and were compared by the log-rank test. The prognostic factors for survival were analyzed by Cox regression analysis. Analysis was carried out using SPSS-16 statistical software (IBM, Atlanta, USA). The median follow up for the whole group was 73 months (range 12.50-292 months).
Results
A total of 213 (61%) patients achieved complete response (CR), 62 (17.8%) had very good partial response (VGPR), 42 (12.0%) partial response (PR) and 14 (4.0%) patients had stable disease. Eighteen (5.2%) patients died of transplant-related complications (before day 100).
Post-transplant complete response (CR) rate according to pre-transplant status:
Among patients with pre-transplant VGPR, 70 (42/60) per cent achieved CR post-transplant, CR rate was 45.5 per cent for those in PR, 23 per cent for those with stable disease and 12.5 per cent for patients with progressive disease pre-transplant (Table II) .
Post-transplant response rate according to primary induction regimen:
Overall response rate (CR+VGPR+PR) was higher for patients who Abbreviations are as given in Table I Months Cumulative survival (Table IV) .
Predictors of progression-free survival (PFS):
Patients with DSS Stage IIIA (P<0.02), transplant within 12 months of diagnosis (P<0.03), novel agents-based induction (P<0.001), pre-transplant chemosensitive disease (P<0.001) and achievement of CR post-transplant (P<0.001) were associated with superior PFS. The presence of extramedullary disease (P<0.001), transplant in second or subsequent remission post-salvage therapy (P<0.001), Hb ≤10 g/dl (P<0.05) and albumin <3.5 g/dl (P<0.001) were predictors of inferior PFS (Table V) .
Multivariate analysis for overall and progression-free survival:
Serum albumin (<3.5 g/dl), presence of ISS, international staging system; DSS, Durie-Salmon staging system; BM-PC, bone marrow plasma cell; EMD, extra-medullary disease; Hb, haemoglobin; VAD, vincristine, adriamycin and dexamethasone; Ig, immunoglobulin; OS, overall survival. Abbreviations are as given in Table I extramedullary disease and ISS Stage III were predictors for inferior OS. Achievement of CR post-transplant and transplant in first remission were predictors for superior OS. Achievement of CR post-transplant and transplant in first remission were predictors for superior PFS (Table VI) .
Current status: In a follow up of patients done in 2018, 184 of 349 patients (52.7%) were alive; 134 (38.4%) Abbreviations are as given in Table IV progression free, 25 (7.2%) with disease and were on salvage therapy, 17 (4.9%), were in second CR after salvage therapy and eight (2.3%) patients had low level serum M spike, <1 g/dl (MGUS like). A total of 164 (47.1%) patients died; these included -18 (5.2%) deaths before day 100 (TRM), 129 (37.0%) due to progressive disease and its complications and 17 patients (4.9%) due to unrelated reasons. Causes included second malignancy in five (myelodysplastic syndrome -1, acute myeloid leukaemia -1, renal cell cancer -1, hepatocellular carcinoma -1, carcinoma tongue -1), dengue fever in two, coronary artery disease in six, cerebral haemorrhage, Alzheimer's disease, acute graft versus host disease and ventilatorassociated complications in one patient each. Status was unknown for one patient.
Discussion
Post-transplant high CR rate, higher median OS (90 months) and PFS (41 months) with 10 yr survival rate of 40.4 and 28.2 per cent, respectively, are important findings in the present study. More than one-third of patients had high-risk disease at diagnosis. Post-transplant overall response rate (90.8%) was high in the present study; this was similar to earlier observations 13, 14, 22 . Conversion to post-transplant CR from pre-transplant response -very good PR (70%), PR (45.5%) and 23 per cent CR in those with stable disease reflected contribution by transplant in augmenting the response already achieved with pretransplant therapy. Post-transplant CR rate was not significantly different between doublet versus triplet regimen. At present, it is recommended to use triplet (three-drug combinations) 2, 13 ; however, there is no direct comparison between different triplets being used currently (VTD vs. VRD vs. VCD). There is also suggestion that four cycles of induction may be adequate and more may not be better 27 .
A median OS and PFS of 90 and 41 months\in our study is similar to earlier studies [15] [16] [17] [18] [19] [20] reporting longterm transplant results. An estimated OS at 10 and 15 yr (40.4 and 17.7%, respectively) indicated prolonged survival in some patients. Similarly, PFS of 15.6 per cent at 15 yr was indicative of a functional cure in a subgroup of patients. A long-term follow up is still needed in the absence of a plateau in survival curve 28 . Achievement of CR post-transplant and transplant in first remission were important predictors of OS and PFS. For those who achieved CR, median OS was 150 months (95% CI 123.5-184.8), significantly higher to those with VGPR and PR. These findings were similar to earlier studies 29 . Achievement of CR post-transplant has been identified as an important marker of longterm survival and is considered to be a desirable goal. Recent studies have suggested that achievement of 'nil' minimal residual disease (MRD) status on multiparameter flow cytometry is a better surrogate marker of long-term survival 30 .
In the present study, 'day +100' TRM was 5.2 per cent; this was higher than the current standard of one per cent or less 13 . Important predictive factors of higher mortality were low serum albumin (<3.5 g/dl) and low estimated GFR (<40 ml/min) at diagnosis and transplant in second or subsequent remission. A reduction in TRM could be due to a combined effect of better case selection, better supportive care and use of novel agents leading to higher response rates including CR which resulted in better depth of response post-transplant and better PFS and OS. Five patients (5/18) had graft failure; three of these had CD34+ stem cells <2 million and two patients had 3.38 and 6.70 million, respectively. In the present study, 56 patients received stem cells cryopreserved at −80°C, the remaining 293 patients received stem cells kept at 4°C. There was no difference in outcome OS and PFS in the two groups. This was consistent with earlier observations from our centre 22 and those reported recently 31 . No difference was observed in outcome of patients who received ≤4 million CD34+ stem cells or more. Abbreviations are as given in Table IV Lack of cytogenetic/FISH (florescent in situ hybridization) data was an important limitation of the present study for most patients.
In conclusion, the findings of the present study showed higher response rate to transplant translating into improved progression free and overall survival. Reducing TRM to <1 per cent and further improvement in CR rates and long-term survival remain desirable goals in future studies.
